Trials & Tribulations Are we focused on the wrong risk type in genetic screening?Breast cancer screening study shows new paths to population screening May 24, 2024Vol.50 No.21By Cassie Hajek
HRD results can vary widely, depending on what assay you choose—even as they guide treatment choices May 17, 2024Vol.50 No.20By Jacquelyn Cobb
RWE study pinpoints gaps in mental health care utilization among parents of children with cancer May 17, 2024Vol.50 No.20By McKenzie Prillaman
Trials & Tribulations Single-cell based precision oncology: First steps in addressing and overcoming tumor heterogeneity May 10, 2024Vol.50 No.19By Sanju Sinha and Eytan Ruppin
Trials & Tribulations Canine cancers as models: We have barely tapped the full potential of comparative oncology May 03, 2024Vol.50 No.18By Christina K. Lopes
Pooled analysis questions reliability of an endpoint used in multi-cancer detection trials April 12, 2024Vol.50 No.15By Jacquelyn Cobb
Trials & Tribulations A new standard in cancer care: Integrated screening, stepped collaborative care for common and distressing symptoms April 05, 2024Vol.50 No.14By Jennifer A. Steel
Multi-target FIT aims to offer inexpensive, high-sensitivity alternative to FIT in colorectal cancer screening March 01, 2024Vol.50 No.09By Matthew Bin Han Ong
Trials & Tribulations Cancer AI systems: We need oncologists to help us build trusted models March 01, 2024Vol.50 No.09By Bernard Chien
First-ever commercial TIL therapy: How NCI, Iovance, and Moffitt achieved FDA approval February 23, 2024Vol.50 No.08By Matthew Bin Han Ong
